Development of fluorescence dye and fluorescence probe for bio-molecular image with only domestic technologies

BioActs Co., Ltd. (Jin-woo Park, Head of Research Center)

Medical science and medical technology change day by day. Accordingly, there is a prospect that the dream of prolonging human life may be realized in the near future, and diseases that have not been conquered so far and developing medicines and new drugs become more competitive day by day.

Accordingly, the company is attracting attention with the success of developing fluorescence dye and fluorescence probe for bio-molecular image that can diagnose diseases with a noninvasive method better than minimum invasion. It is most essential to verify the medical effects as well as to prepare a research paper on it.

Spotlighted base fluorescence material in the vortex of
full-scale expansion in molecular image market

With the ever-changing medical science and medical technology development, reagents for medical image, compounds made to improve images from image systems, are playing an important role in the areas of diagnosis, medical drugs, biotechnology, and life science. These reagents are spotlighted as a basic material that can detect metastasis status in the body as well as whether a tumor is benign or malignant, and as a new profit source in the medical market. The reason why medical image reagents are spotlighted like this is recently through molecular imaging, a part of biomedical science that has been evolving rapidly along with advances in image medical science.Untitled-1.jpg

Commonly known X-ray, ultrasound, and CT (computer tomography) visualize anatomical changes caused by diseases, and show the status of already developing diseases. However, given that biochemical and molecular genetic changes occur prior to anatomical changes by diseases, imaging such changes would allow not just appropriate treatment at an early stage, but also customized treatment and prescription for individual patients, because the root cause of the disease can be clarified, and through which, treatment and treatment effect can be determined at an early stage. And, molecular imaging can fulfill such a role, which is why it has developed so quickly recently and is taking center stage.
Moreover, molecular imaging is being highlighted as a new economic power in the 21st-century as it is a converged field where many academic disciplines from molecular & cell biology to image medical science, physics, pharmacy, and chemistry as well as medical science are combined. In a regard that bio-molecular fluorescence dye, especially, a medical image reagent that is an indispensable adjunct to molecular imaging, plays a role of maximizing the advantages of molecular imaging, it is expected that technology security and relevant product development will come into play as a power source that allows advancement into an intensively competitive medical market.

High stability and an advantage allowing long-time preservation

In this situation, it is significant that Jin-woo Park, head of the technical research center affiliated with DKC Corporation (Jongsoo Na, CEO), which has specialized in manufacturing textile dyes for almost 40 years since its establishment in 1976, succeeded in developing bio-molecular fluorescence dye and fluorescence probe entirely with domestic technology. In relation to this, Mr. Park who led this development said that “Over 40 years of dye research developing and manufacturing experience was a big advantage. Since all mass-production facilities for textile dyes were moved to China in early 2000, various attempts have been made to secure new sources of growth. In this course, we developed fluorescence dye and fluorescence probe for optical bio-molecular image.”Untitled-2.jpg
And he added that “Most of all, this product can 100% substitute for what we totally relied on imports for acquiring before through this development, which would lead to much better research performance due to the improved research environment as well as satisfying potential demand from universities, companies, and organizations, that have restrictions in research activities due to high price and limited supply. This is expected to give a boost not only to medicine and new drug development including anticancer drug development but also to the domestic optical imaging field.”
In addition to import substitution effect, DKC Corporation’s bio-molecular image fluorescence dye allows long time preservation with high stability and also it is very effective for users who handle complicated bio-molecular. Therefore, through products composition combined with outstanding product stability and various fluorescence-quenching wavelengths and reactors, unlimited new optical image application research and product development would be derived in chemical • biochemical • medical • pharmaceutical fields. Also, there are sufficient demands as a substitution for existing fluorescence product by domestic and foreign antibodies, peptide, related product manufacturers. Therefore, sudden sales increases are expected along with expanding commercialization in fluorescence products using diagnosis, treatment, and clinical researches.

Indeed, DKC Corporation already commercialized 16 types of fluorescence chromogen usable in whole visible light-near infrared wavelength areas and 60 types of fluorescence probe where various reactors were introduced, under the brand name, Flamma Fluors family. DKC achieved 620 billion won of sales in last year only, and more than double this amount of growth the amount of this growth growth is expected every year starting with 2.5 billion won in this year. In this matter, Mr. Park said that “Fluorescence dye light bead
& optical contrast products and biomaterial marking products are high value products as they are sold for 100~500 dollars per 1mg and in the unit of ug~ng. Because fluorescence equipment for research comes into wide use and demand increase is expected for base fluorescence materials due to full-scale expansion in clinical molecular diagnosis market, we are confidence for its industrialization potential and growth potential”

‘BioActs,’ the fruit of choice and concentration, foretells a gust in the market

Meanwhile, this technical development of DKC Corporation has another success factor. That is, ‘choice and concentration.’ DKC Corporation, which has consolidated its position as a specialized textile dye manufacturer for nearly 40 years since its establishment in 1976 started bio-dye development based on accumulated techniques in order to secure new source of growth power as it moved textile dye manufacturing business to China in early 2000. Creating the ‘BioActs’ business unit in January 2009, DKC started full-scale research development and product development. It changed the company name to BioActs in June this year, and advanced to be the nation’s best company for biomolecular image fluorescence dye and fluorescence probe, expanding research manpower and facilities and business foundation. This grabs attention as a model case that achieved good performance through quick choice for a new business group based on ccumulated base technology and know-how to find new sources of growth power, and concentration on high potential fields.

Untitled-3.jpgAs a result, BioActs already received proposals for technology transfer and joint development from research institutions and company research centers as well as famous domestic and foreign universities and hospitals. Now, they are progressing researches to secure new fluorescence probe that can be used for both in-vivo and in-vitro searches and diagnosis, and to advance into the clinical image contrast market comprehensively through collaboration work and affiliation with these organizations, in addition to joint governmental tasks & research development and company specialized product supply.
Regarding this, Mr. Park revealed that “While focusing on the development and industrialization of bio-molecular fluorescence dye, base optical materials for in-vitro diagnosis products, and near-infrared substances and contrast media for probe research and development used in-vivo search, BioActs is preparing GMP based FDA authorized fluorescence dye including ICG and MB in the long term. More specifically, we are preparing the clinic endoscope and operation aid fluorescence marker.” and “Although there is high entry barrier by existing foreign companies dominating the market, we will overcome the barrier based on the source technology of fluorescence dye and probe manufacturing secured through this development, and become the biggest company recognized world widely as well as domestically in this field.” | Blog Magazine of Korean products, brands and Goods